Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Hematology
    • Hereditary Genetic Disorders
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Diseases
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://jheor.org/feed
×
Oncology
Vol. 3, Issue 2, 2016October 21, 2015 EDT

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy

Gabriel Tremblay, Unnati Majethia, Ilias Kontoudis, Jesús De Rosendo,
spain cost-utility cost-effectiveness eribulin her2-negative metastatic breast cancer
Copyright Logoccby-4.0 • https://doi.org/10.36469/9834
Photo by Ken Treloar on Unsplash
JHEOR
1.
Tremblay G, Majethia U, Kontoudis I, De Rosendo J. Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy. JHEOR. 2015;3(2):180-193. doi:10.36469/9834
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)

View more stats

Powered by Scholastica, the modern academic journal management system